AI주식인사이트AI Stock Insight
B

씨젠

096530KOSDAQ

59.0 / 100

Reference Date: 2026-10-23

Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum15.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 5.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Seegene is a molecular diagnostics specialist established in 2000, leveraging DNA/RNA analysis to detect disease causes, with 91% of its revenue from exports globally. The company utilizes its proprietary Syndromic qPCR technology and 19 patents to develop multiplex diagnostic products, and is expanding AI-driven diagnostic reagent development through collaborations with Microsoft and Springer Nature.

Number of Employees

822people

Average Salary

95.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
32.94Industry Average 15.000.0Point

2.2x industry avg (risky)

PBR
1.57Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
4.82Industry Average 8.002.5Point

Below industry avg

Debt Ratio
4.85Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲177.4% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 1.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (72%)

Current 34,150Won52-week high 38,80052-week low 21,850
1-month return4.0Point

1m +5.89% (slight rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-10-21
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-10-19
  • Positive중간(분기)배당락2026-09-28